Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vera Grossmann

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Molecular Diagnostics : JMD|March 1, 2011
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyVera Grossmann, Susanne Schnittger, Sonja Schindela, et al.
Haematologica|August 10, 2012
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangementsAndrew Chase, Catherine Bryant, Joannah Score, et al.
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Robustness of amplicon deep sequencing underlines its utility in clinical applicationsVera Grossmann, Andreas Roller, Hans-Ulrich Klein, et al.
Blood|March 24, 2012
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entityUlrike Bacher, Susanne Schnittger, Katja Macijewski, et al.
Genes, Chromosomes & Cancer|January 24, 2013
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALLVera Grossmann, Claudia Haferlach, Sandra Weissmann, et al.
British Journal of Haematology|March 26, 2013
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosisVera Grossmann, Claudia Haferlach, Niroshan Nadarajah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, et al.
British Journal of Haematology|December 31, 2013
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impactUlrike Bacher, Torsten Haferlach, Susanne Schnittger, et al.
Haematologica|June 27, 2012
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 casesSusanne Schnittger, Ulrike Bacher, Tamara Alpermann, et al.
Blood|August 25, 2012
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Molecular Diagnostics : JMD|March 1, 2011
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyVera Grossmann, Susanne Schnittger, Sonja Schindela, et al.
Haematologica|August 10, 2012
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangementsAndrew Chase, Catherine Bryant, Joannah Score, et al.
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Robustness of amplicon deep sequencing underlines its utility in clinical applicationsVera Grossmann, Andreas Roller, Hans-Ulrich Klein, et al.
Blood|March 24, 2012
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entityUlrike Bacher, Susanne Schnittger, Katja Macijewski, et al.
Genes, Chromosomes & Cancer|January 24, 2013
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALLVera Grossmann, Claudia Haferlach, Sandra Weissmann, et al.
British Journal of Haematology|March 26, 2013
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosisVera Grossmann, Claudia Haferlach, Niroshan Nadarajah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, et al.
British Journal of Haematology|December 31, 2013
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impactUlrike Bacher, Torsten Haferlach, Susanne Schnittger, et al.
Haematologica|June 27, 2012
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 casesSusanne Schnittger, Ulrike Bacher, Tamara Alpermann, et al.
Blood|August 25, 2012
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Pageof 4